Glenmark signs deal with Novartis over distribution in Brazil

pharmafile | June 24, 2019 | News story | Sales and Marketing Brazil, Glenmark, Latin America, Novartis, distribution, pharma 

Indian firm Glenmark Pharmaceuticals has entered into an agreement with Novartis over the distribution of its respiratory products in Brazil.

Novartis will distribute three of Glenmark’s COPD drugs in Brazil from 1 July 2019.

The Swiss firm will be responsible for promoting, commercialising and distributing Glenmark’s Seebri (Glycopyrronium bromide), Onbrize (Indacaterol) and Ultibro (combination of Indacaterol and Glycopyrronium) – all of which treat the symptoms of COPD.

“This partnership is in line with our vision to expand our respiratory product offerings for patients and prescribers in Brazil and further consolidate our position in this segment,” said Glenn Saldanha, Chairman and Managing Director of Glenmark.

Glenmark receives around 5% of its revenue from Latin America. However Indian generic drugmakers – who are now facing pricing pressures in the US – are increasingly focused on increasing sales in big markets such as Brazil.

Louis Goss

Related Content

FDA approves IMIDEX’s AI-powered device VisiRad XR

The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …

Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo

On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …

Ionis and Novartis partner for CVD treatment programme

Ionis Pharmaceuticals has announced that it has entered into a new collaboration and license agreement …

Latest content